GPCR VideoCast << Back to VideoCast list Dr. Juan José Fung About Dr. Juan José Fung Dr. Juan José Fung is a Principal Scientist at GPCR Therapeutics, Inc , a drug discovery company focused on targeting GPCR heteromers in cancer, headquartered in Seoul, Korea, with an R&D facility in the SF Brian Kobilka , studying the dimerization of GPCRs. Dr. Juan José Fung on the web LinkedIn GPCR Therapeutics Dr.

GPCR Podcast << Back to podcast list Dr. Arthur Christopoulos About Dr. Juan José Fung Dr. Juan José Fung is a Principal Scientist at GPCR Therapeutics, Inc , a drug discovery company focused on targeting GPCR heteromers in cancer, headquartered in Seoul, Korea, with an R&D facility in the SF Brian Kobilka , studying the dimerization of GPCRs. Dr. Juan José Fung on the web LinkedIn GPCR Therapeutics Dr.

GPCR Symposia 2023 Last Friday, September 22nd, we had our Symposium GPCRs as Therapeutic Modalities. , Inoviem Scientific Lauren Slosky , University of Minnesota Medical School Christel Menet , Confo Therapeutics Ben Myers , University of Utah Niña Caculitan , GPCR Therapeutics Watch the GPCRs as Therapeutic Modalities Ecosystem Partners We thank Domain Therapeutics , GPCR Therapeutics , Design Pharmaceuticals , Montana Take a look at the latest news classified by topic: Adhesion GPCRs GPCR Activation and Signaling GPCR

topic of GPCRs as Therapeutic Targets. Christel Menet , CSO at Confo Therapeutics Nina Caculitan , Director of Clinical Development at GPCR Therapeutics Terry Kenakin , Professor at the University of North Carolina Sam Hoare , Kinetic Data Analyst Ecosystem Partners We thank Domain Therapeutics , GPCR Therapeutics , Design Pharmaceuticals , Montana Take a look at the latest news classified by topic: Adhesion GPCRs GPCR Activation and Signaling GPCR

Pina Cardarelli, CSO for GPCR Therapeutics Inc., based in South Korea, has recently been named President of GPCR Therapeutics, USA, a newly incorporated Biotechnology company in the Bay Area. The company’s mission is to discover and develop highly effective cancer therapeutics by targeting heteromers She was an integral contributor to two therapeutics that are FDA approved, Yervoy and Opdivo. patents including anti-PD-1 patents, 22 EP patents, and greater than 100 global patents centered around therapeutic

Pina Cardarelli, CSO for GPCR Therapeutics Inc., based in South Korea, has recently been named President of GPCR Therapeutics, USA, a newly incorporated Biotechnology company in the Bay Area. The company’s mission is to discover and develop highly effective cancer therapeutics by targeting heteromers She was an integral contributor to two therapeutics that are FDA approved, Yervoy and Opdivo. patents including anti-PD-1 patents, 22 EP patents, and greater than 100 global patents centered around therapeutic

GPCR Newsletter May, 2023 Hello Readers, Welcome to our monthly Dr. GPCR Newsletter! GPCR Ecosystem member , which is also free! Dr. GPCR Podcast As a premium Dr. Ecosystem Partners We are grateful to Domain Therapeutics , GPCR Therapeutics , Design Pharmaceuticals GPCR News Classified GPCR News We hope you are enjoying our weekly news, directly delivered to your inbox Take a look at the latest news classified by topic: Adhesion GPCRs GPCR Activation and Signaling GPCR

GPCR Newsletter July, 2023 Hello Readers, Welcome to our monthly Dr. GPCR Newsletter! The Dr. as Therapeutic Targets. Ecosystem Partners We thank Domain Therapeutics , GPCR Therapeutics , Design Pharmaceuticals , Montana Take a look at the latest news classified by topic: Adhesion GPCRs GPCR Activation and Signaling GPCR and Molecular Insights into GPCR Function Industry News Call for GPCR Papers GPCR Events, Meetings,

GPCR Symposium on Understanding Challenging GPCRs was held last week and it was a fantastic day filled GPCR Podcast As a premium Dr. Ecosystem Partners We are grateful to Domain Therapeutics , GPCR Therapeutics , Design Pharmaceuticals friends at Orion Biotechnology published their first news in the Ecosystem entitled ‘’ Unlocking the Therapeutic Insights into GPCR Function Industry News Call for GPCR Papers GPCR Events, Meetings, and Webinars GPCR

Ecosystem Partners We are grateful to Domain Therapeutics , GPCR Therapeutics , Design Pharmaceuticals GPCR at the 2nd GPCR Targeted Drug Discovery Summit 2023 Join us February 21-23, 2023 in Boston. GPCR Podcast As a premium Dr. friends at Orion Biotechnology published their first news in the Ecosystem entitled ‘’ Unlocking the Therapeutic Insights into GPCR Function Industry News Call for GPCR Papers GPCR Events, Meetings, and Webinars GPCR

GPCR Newsletter April, 2023 Hi there Dr. GPCR community! Welcome to our monthly Dr. GPCR Podcast As a premium Dr. Ecosystem Partners We are grateful to Domain Therapeutics , GPCR Therapeutics , Design Pharmaceuticals GPCR Activation and Signaling GPCR Binders, Drugs, and more GPCRs in Cardiology, Endocrinology, and for GPCR Papers GPCR Events, Meetings, and Webinars GPCR Jobs Previous Subscribe to our Monthly Newsletter

GPCR Newsletter June, 2023 Hello Readers, Welcome to our monthly Dr. GPCR Newsletter! GPCR Symposium on Structural and Molecular Insights on GPCR Activation . Ecosystem Partners We thank Domain Therapeutics , GPCR Therapeutics , Design Pharmaceuticals , Montana Take a look at the latest news classified by topic: Adhesion GPCRs GPCR Activation and Signaling GPCR and Molecular Insights into GPCR Function Industry News Call for GPCR Papers GPCR Events, Meetings,

Ecosystem Partners We are grateful to Domain Therapeutics , GPCR Therapeutics , Design Pharmaceuticals GPCR Ecosystem this year. GPCR at the 2nd GPCR Targeted Drug Discovery Summit 2023 We are thrilled to partner with the organizers Take a look at the latest news classified by topic: GPCR Activation and Signaling GPCR Binders, Drugs Insights into GPCR Function Industry News Call for GPCR Papers GPCR Events, Meetings, and Webinars GPCR

GPCR Newsletter December, 2023 Hello Readers, Welcome to our monthly Dr. GPCR Newsletter! GPCR Access to Dr. Ecosystem Partners We thank Domain Therapeutics , GPCR Therapeutics , Design Pharmaceuticals , Montana Take a look at the latest news classified by topic: Adhesion GPCRs GPCR Activation and Signaling GPCR and Molecular Insights into GPCR Function Industry News Call for GPCR Papers GPCR Events, Meetings,

GPCR Newsletter October, 2023 Hello Readers, Welcome to our Dr. GPCR monthly Newsletter! Dr.GPCR at Great Lakes GPCR Retreat The GPCR Retreat is just around the corner! Ecosystem Partners We thank Domain Therapeutics , GPCR Therapeutics , Design Pharmaceuticals , Montana Take a look at the latest news classified by topic: Adhesion GPCRs GPCR Activation and Signaling GPCR and Molecular Insights into GPCR Function Industry News Call for GPCR Papers GPCR Events, Meetings,

We want to thank our partner Domain Therapeutics for their support and for helping us bring you to this Domain Therapeutics is a biopharmaceutical company committed to discovering and developing innovative Twist Biopharma provides end-to-end Solutions in Biologics Discovery & Early Development/ GPCR Therapeutics GPCR Therapeutics's mission is to discover and develop innovative therapeutics targeting cancer based in Oncology and Immunology In vivo monitoring of the therapeutic efficacy of a CXCR1/2 inhibitor with

GPCR Newsletter November, 2023 Hello Readers, Welcome to our monthly Dr. GPCR Newsletter! Insights in GPCR Function October 11th - GPCRs as Therapeutic Modalities Are you a Premium Member ? Ecosystem Partners We thank Domain Therapeutics , GPCR Therapeutics , Design Pharmaceuticals , Montana Take a look at the latest news classified by topic: Adhesion GPCRs GPCR Activation and Signaling GPCR and Molecular Insights into GPCR Function Industry News Call for GPCR Papers GPCR Events, Meetings,

Juan Jose Fung , principal scientist at GPCR Therapeutics followed by Dr. Nicola Smith and Dr. Pina Cardarelli , CSO of GPCR Therapeutics. Are you going to be our next podcast guest? Odorant G protein-coupled receptors as potential therapeutic targets for adult diffuse gliomas: a systematic G-protein-coupled receptors as therapeutic targets for glioblastoma. , and Regulation to Therapeutics joint with Micropeptides: Biogenesis and Function, April 6-9, 2022 Great

We want to thank our partner Domain Therapeutics for their support and for helping us bring you this Domain Therapeutics is a biopharmaceutical company committed to discovering and developing innovative Twist Biopharma provides end-to-end Solutions in Biologics Discovery & Early Development/ GPCR Therapeutics GPCR Therapeutics's mission is to discover and develop innovative therapeutics targeting cancer based Revealed: Disentangling the Pharmacology to Open Up New Therapeutic Strategies Biacore™ SPR machine

A correlation study of adhesion G protein-coupled receptors as potential therapeutic targets in Uterine inflammation. 1.8 Reviews Oxytocin and vasopressin: Signalling, behavioural modulation and potential therapeutic Comprehensive insights in GRK4 and hypertension: From mechanisms to potential therapeutics. 2. Glenn Vraniak as Chief Financial Officer Domain Therapeutics Raises $42m Series A Financing Sosei Heptares Therapeutics Expands Scientific Advisory Board by welcoming Dr.

Therapeutics Ines Liebscher , Leipzig University Christel Menet , Confo Therapeutics Vladimir Katanaev trafficking as a therapeutic avenue for misfolded GPCRs leading to endocrine diseases Multitargeting Dynamic mechanism of GPCR-mediated β-arrestin: a potential therapeutic agent discovery of biased drug Wainwright 24th Annual Investment Conference GPCR Therapeutics, USA officially opened its doors in its to discover therapeutic antibodies on GPCRs Inversago Pharma receives IND clearance for Phase 2 trial

Ecosystem Partners We are grateful to Domain Therapeutics , GPCR Therapeutics , Design Pharmaceuticals Professor and Deputy Director, Neuromedicines Discovery Centre at Monash University and CEO of Phrenix Therapeutics Atypical chemokine receptors: emerging therapeutic targets in cancer. Reports Q3 2022 Financial Results and Provides Corporate Update Peter Suzdak, Ph.D. joins Function Therapeutics NBI-1117568 is an Investigational, First-in-Class, Muscarinic M4 Selective Agonist Confo Therapeutics

Ecosystem Partners We are grateful to Domain Therapeutics , GPCR Therapeutics , Design Pharmaceuticals in Cardiology, Endocrinology, and Taste GRK2 in cardiovascular disease and its potential as a therapeutic Comprehensive insights in GRK4 and hypertension: From mechanisms to potential therapeutics. GPCRs as an emerging host-directed therapeutic target against mycobacterial infection: From notion to Allosteric Modulator Discovery Collaboration Domain Therapeutics strengthens Scientific Advisory Board

Pina Cardarelli from GPCR Therapeutics as well as Dr. Marta Filizola. Towards Novel Therapeutics for Inflammatory Bowel Diseases GPR40 agonist inhibits NLRP3 inflammasome endocytosis of GPCRs: implications in pathophysiology and therapeutics Somatostatin and Its Receptor OB-004 is a GPCR targeted protein analog of CCL2 that targets the CCR2 receptor OMass Therapeutics's , and Regulation to Therapeutics joint with Micropeptides: Biogenesis and Function, April 6-9, 2022 Great

A special thanks to our Ecosystem Partners , Domain Therapeutics , GPCR Therapeutics , Design Pharmaceuticals GPCR Ecosystem. Lysosomal GPCR-like protein LYCHOS signals cholesterol sufficiency to mTORC1 A cryptic mode of GPCR regulation Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1117568 in Adults with Schizophrenia Confo Therapeutics Paul Ornstein recently joined Function Therapeutics, Inc. as VP of Preclinical Development Trevena Announces

GPCR at the Great Lakes GPCR Retreat : We are happy to announce that Dr. GPCR has affected you and the field today . GPCR News 1. Will ETA-antibody arouse new interest in cancer therapeutics? Therapeutics welcomes Dr. Development Orion Shares New Data on its Latest Best-in-Class Drug Candidate New publication from Confo Therapeutics

We'd also like to express our gratitude to our partners for their support: Domain Therapeutics , a biopharmaceutical GPCR Therapeutics with the mission is to discover and develop innovative therapeutics targeting cancer drug discovery Pre-clinical evaluation of dual targeting of the GPCRs CaSR and V2R as therapeutic strategy : Signaling, Crosstalk, and Therapeutic Targeting Signaling Microdomains in the Spotlight: Visualizing Receptors Revealed: Disentangling the Pharmacology to Open Up New Therapeutic Strategies Biacore™ SPR

Juan José Fung from GPCR Therapeutics , Dr. Rosie Dawaliby , CEO of G-Clips Biotech , Dr. CCR8 is a new therapeutic target in cutaneous T-cell lymphomas. Ross Bathgate becomes Scientific co-founder of LASEREDD Therapeutics X4 slashes pipeline and lays off Tectonic Therapeutic Strengthens Leadership Team G.CLIPS biotech is 2 years old this month! Confo Therapeutics receives €1.7 million VLAIO grant for further research on GPCR modulators for rare